Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Emerg. Microbes Infect., Published online:27 Sep 2022, Dec;11(1):2315-2325 | https://doi.org/10.1080/22221751.2022.2117094
